The stake has been purchased by Biomab Brilliant Limited, a British Virgin Islands-based company which holds the remaining 75% stake.
The transaction is valued at about 165 cr in Indian rupees.
“The closing of the transaction is subject to conditions precedent and receipt of applicable regulatory and other approvals,” Cipla said.
Headquartered in Mumbai, the company has manufacturing facilities in Goa, Bengaluru, Baddi, Indore, Kurkumbh, Patalganga, and Sikkim, along with field stations in Delhi, Pune, and Hyderabad.
Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control and depression.